<p>Proportion of patients with HIV-1 RNA < 50 copies/mL (ITT FDA snapshot analysis) at weeks 48, 96 and 144.</p
Proportion of medication adherence among patients attending HIV clinics in two cities as measured by...
Proportion of medication adherence among patients attending HIV clinics in two cities as measured by...
<p>Percentage of HIV-1 strains circulating worldwide that could be neutralized by mAbs 2219 and 447-...
<p>Proportion of subjects with plasma HIV-1 RNA<48 copies/mL and <200 copies/mL using the Intention-...
Proportion of responders with HIV-1 RNA <40 copies/mL (Week 24 snapshot) (mITT).</p
Proportion of participants with plasma HIV-1 RNA <50 c/mL through week 48 by intention to treat (mis...
<p>(A) Per protocol analysis. (B) Intention-to-treat analysis. VL, viral load; RAL, raltegravir; DRV...
<p>Mantel-Haenszel odds ratio of ART experienced HIV-1 patients who achieved HIV-1 RNA < 50 copies p...
<p>Mantel-Haenszel odds ratio of ART experienced HIV-1 patients who achieved HIV-1 RNA < 400 copies ...
<p>(<b>A</b>) Final HIV-1 RNA and (<b>B</b>) final CD4 cell counts by calendar year for 1,814 unique...
<p>The proportion of patients with a detectable viral load (≥400 copies/ml) at study visits using th...
<p>Mantel-Haenszel odds ratio of ART experienced HIV-1 patients with HIV-1 RNA reduction ≥1 log<sub>...
<p>Factors associated with HIV RNA <1000 copies/ml among HIV patients receiving first-line ART at 12...
<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095524#pone-0095524-g002" ...
<p>Data is presented as median and range. 49 copies is the lower limit of detection of the assay, an...
Proportion of medication adherence among patients attending HIV clinics in two cities as measured by...
Proportion of medication adherence among patients attending HIV clinics in two cities as measured by...
<p>Percentage of HIV-1 strains circulating worldwide that could be neutralized by mAbs 2219 and 447-...
<p>Proportion of subjects with plasma HIV-1 RNA<48 copies/mL and <200 copies/mL using the Intention-...
Proportion of responders with HIV-1 RNA <40 copies/mL (Week 24 snapshot) (mITT).</p
Proportion of participants with plasma HIV-1 RNA <50 c/mL through week 48 by intention to treat (mis...
<p>(A) Per protocol analysis. (B) Intention-to-treat analysis. VL, viral load; RAL, raltegravir; DRV...
<p>Mantel-Haenszel odds ratio of ART experienced HIV-1 patients who achieved HIV-1 RNA < 50 copies p...
<p>Mantel-Haenszel odds ratio of ART experienced HIV-1 patients who achieved HIV-1 RNA < 400 copies ...
<p>(<b>A</b>) Final HIV-1 RNA and (<b>B</b>) final CD4 cell counts by calendar year for 1,814 unique...
<p>The proportion of patients with a detectable viral load (≥400 copies/ml) at study visits using th...
<p>Mantel-Haenszel odds ratio of ART experienced HIV-1 patients with HIV-1 RNA reduction ≥1 log<sub>...
<p>Factors associated with HIV RNA <1000 copies/ml among HIV patients receiving first-line ART at 12...
<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095524#pone-0095524-g002" ...
<p>Data is presented as median and range. 49 copies is the lower limit of detection of the assay, an...
Proportion of medication adherence among patients attending HIV clinics in two cities as measured by...
Proportion of medication adherence among patients attending HIV clinics in two cities as measured by...
<p>Percentage of HIV-1 strains circulating worldwide that could be neutralized by mAbs 2219 and 447-...
DOI
Add to ORKG